{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Studies on tumor tissue obtained during baseline /previous biopsy (if available), Cycle 1 Day 4(+/- 3 days), and possible treatment evaluation following Course 1. Plasma and blood will also be collected.","groups":[{"description":"Phase I Dose Level 1 Mithramycin 60 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses..","id":"OG000","title":"Phase I Dose Level 1 Mithramycin 60 mcg/kg"},{"description":"Phase I Dose Level -1 Mithramycin 60 mcg/kg followed by Mithramycin 30 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses.","id":"OG001","title":"Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg"}],"populationDescription":"No data was collected thus this outcome measure was not done.","reportingStatus":"POSTED","timeFrame":"baseline, Cycle 1 Day 4 (+/- 3 days), and possible treatment evaluation following Course 1","title":"To Develop Methodologies for Assessing Effects of Mithramycin on Cancer Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Circulating Tumor Cells (CTC)","type":"SECONDARY"}